Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial.
Valgimigli M, Percoco G, Barbieri D, Ferrari F, Guardigli G, Parrinello G, Soukhomovskaia O, Ferrari R. Valgimigli M, et al. Among authors: guardigli g. J Am Coll Cardiol. 2004 Jul 7;44(1):14-9. doi: 10.1016/j.jacc.2004.03.042. J Am Coll Cardiol. 2004. PMID: 15234398 Free article. Clinical Trial.
High-dose bolus tirofiban and sirolimus eluting stent versus abiciximab and bare metal stent in acute myocardial infarction (STRATEGY) study--protocol design and demography of the first 100 patients.
Valgimigli M, Percoco G, Cicchitelli G, Ferrari F, Barbieri D, Ansani L, Guardigli G, Parrinello G, Malagutti P, Soukhomovskaia O, Bettini A, Campo G, Ferrari R. Valgimigli M, et al. Among authors: guardigli g. Cardiovasc Drugs Ther. 2004 May;18(3):225-30. doi: 10.1023/B:CARD.0000033644.91126.f7. Cardiovasc Drugs Ther. 2004. PMID: 15229391 Clinical Trial.
Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial.
Valgimigli M, Percoco G, Malagutti P, Campo G, Ferrari F, Barbieri D, Cicchitelli G, McFadden EP, Merlini F, Ansani L, Guardigli G, Bettini A, Parrinello G, Boersma E, Ferrari R; STRATEGY Investigators. Valgimigli M, et al. Among authors: guardigli g. JAMA. 2005 May 4;293(17):2109-17. doi: 10.1001/jama.293.17.2109. JAMA. 2005. PMID: 15870414 Clinical Trial.
Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) study.
Valgimigli M, Ceconi C, Malagutti P, Merli E, Soukhomovskaia O, Francolini G, Cicchitelli G, Olivares A, Parrinello G, Percoco G, Guardigli G, Mele D, Pirani R, Ferrari R. Valgimigli M, et al. Among authors: guardigli g. Circulation. 2005 Feb 22;111(7):863-70. doi: 10.1161/01.CIR.0000155614.35441.69. Epub 2005 Feb 7. Circulation. 2005. PMID: 15699251
Oxidative stress during myocardial ischaemia and heart failure.
Ferrari R, Guardigli G, Mele D, Percoco GF, Ceconi C, Curello S. Ferrari R, et al. Among authors: guardigli g. Curr Pharm Des. 2004;10(14):1699-711. doi: 10.2174/1381612043384718. Curr Pharm Des. 2004. PMID: 15134567 Review.
Serum from patients with acute coronary syndromes displays a proapoptotic effect on human endothelial cells: a possible link to pan-coronary syndromes.
Valgimigli M, Agnoletti L, Curello S, Comini L, Francolini G, Mastrorilli F, Merli E, Pirani R, Guardigli G, Grigolato PG, Ferrari R. Valgimigli M, et al. Among authors: guardigli g. Circulation. 2003 Jan 21;107(2):264-70. doi: 10.1161/01.cir.0000045665.57256.86. Circulation. 2003. PMID: 12538426 Clinical Trial.
A modern fairy tale.
Ferrari R, Guardigli G, Tavazzi L. Ferrari R, et al. Among authors: guardigli g. Eur J Cardiovasc Prev Rehabil. 2009 Aug;16 Suppl 2:S65-7. doi: 10.1097/01.hjr.0000359241.90303.37. Eur J Cardiovasc Prev Rehabil. 2009. PMID: 19675442 No abstract available.
68 results